2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOCompleted
This pilot study aims to confirm the feasibility of the PET scan procedure in 4 healthy volunteers to quantify NET binding in humans. This would then lay the foundation for intended future studies in our department investigating NET availability in…